Ginsenoside RK3 suppresses osteosarcoma via PRMT5/GPX4-ferroptosis axis and enhances doxorubicin chemosensitivity.

Xu Z, Du Z, Niu Q, Wang X, Wang H, Zhang M, Liu M.

Open source

DOI: 10.3389/fphar.2026.1980493
Published: 2026-10-23
Container: Front Pharmacol
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1980493,
  title = {Ginsenoside RK3 suppresses osteosarcoma via PRMT5/GPX4-ferroptosis axis and enhances doxorubicin chemosensitivity.},
  author = {Xu Z and  Du Z and  Niu Q and  Wang X and  Wang H and  Zhang M and  Liu M.},
  year = {2026},
  journal = {Front Pharmacol},
  doi = {10.3389/fphar.2026.1980493},
  url = {https://doi.org/10.3389/fphar.2026.1980493}
}

RIS

TY  - JOUR
TI  - Ginsenoside RK3 suppresses osteosarcoma via PRMT5/GPX4-ferroptosis axis and enhances doxorubicin chemosensitivity.
AU  - Xu Z
AU  -  Du Z
AU  -  Niu Q
AU  -  Wang X
AU  -  Wang H
AU  -  Zhang M
AU  -  Liu M.
PY  - 2026
JO  - Front Pharmacol
DO  - 10.3389/fphar.2026.1980493
UR  - https://doi.org/10.3389/fphar.2026.1980493
ER  -

APA

Z, X., Z, D., Q, N., X, W., H, W., M, Z., & M., L. (2026). Ginsenoside RK3 suppresses osteosarcoma via PRMT5/GPX4-ferroptosis axis and enhances doxorubicin chemosensitivity.. Front Pharmacol. https://doi.org/10.3389/fphar.2026.1980493

Source records

europe-pmc · retrieved 2026-11-10T10:39:39.652Z
doaj · retrieved 2026-11-10T10:39:39.640Z